Alkyl Amines Chemicals Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cxzrn4htxschmohzu0lamzy4.pdf

Key Takeaways


Volume & Margin Dynamics

Kirat Patel: "We are always optimistic that we will try to improve the margin, but we don't want to sacrifice volume because of it. So, our focus will be more volume than margins, but of course at the same time, we try to expand the margins. But it's difficult to say where we will in the end land up."

Chinese Overcapacity & Pricing Pressure

Udipt Agarwal: "I think it is more of a capacity issue right now and a little bit of inventory effect is still hangover, is carrying on."

Product-Specific Updates

Kirat Patel: "We haven't yet received any protection from the government against the Chinese imports. We have applied very recently for protection, and we hope over the next maybe 9 to 12 months, we will get some protection. But till then the pressure on Monoisopropylamine will continue."

New Product Pipeline & Capex

Kirat Patel: "It is not part of our existing portfolio. It's a new product. It is going to be manufactured in Dahej as has been stated in the SEBI notice. And... yes, it is an import substituted product."

Revenue Mix & End-Market Trends


Guidance & Commitments

CommitmentSpecificsTimeline
Volume growth FY25Hope to cross 10%FY25
Acetonitrile anti-dumping dutyDecision expected after MoC investigation and MoF approvalNext 4–5 months
Monoisopropylamine protectionApplied recently; hope to receive government protectionNext 9–12 months
New product commercializationFirst phase of second new molecule (import-substituted)~15 months
Existing capacity volume growthNormalized volume growth achievable from existing capacityNext 2–3 years
Ethylamines capacity headroomPlenty of headroom; no pressure on capacitiesNext 3–4 years
Land availabilitySufficient land in Dahej and KurkumbhAt least 2–3 years
Next two pipeline productsInvestment decision dependent on market conditionsPerhaps next 6 months or later

Key Metrics

MetricQ2 FY25
RevenueNot stated
Volume growth17% YoY for Q2 FY25
H1 FY25 volume growth8% to 10% YoY
FY25 volume growth guidanceHope to cross 10%
Gross margin movementSqueezed by about 2% half year to half year, as finished good prices dropped 5%-6% while raw material prices dropped 3%-4%
Life sciences revenue share65%-70% of turnover
Domestic/export revenue split80-20
Export shareAbout 20% annually, 20%-21%; quarter-to-quarter varies 18%-22%
Overall capacity utilization65% to 70% on average, varies by product
Acetonitrile market share50% to 55%
Acetonitrile plant utilizationAround 60%
Indian Acetonitrile market size~30,000 tons
Indian Ethylamines market size25,000 to 30,000 tons
Coal costRs. 9,000 to Rs. 10,000 per metric ton, stable across two years (+/-10%)
FY25 capex outlook₹80 to 100 crores
FY26 capex outlook₹100 to 120 crores
New product capex timelineFirst phase in about 15 months; potential debottleneck/expansion within next 3-4 years